Home › Calculator › BNR Dividend Calculator 2026
BNR Dividend DRIP Calculator 2026
21.86% YieldHealthcareBurning Rock Biotech Limited · NASDAQ
Price: $9.15 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When BNR pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your BNR snowball 📈
$10,000 in BNR → $12.64M in 10 years · $224.86/month
About Burning Rock Biotech Limited (BNR) — Dividend Analysis 2026
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.
Compare BNR with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full BNR DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open BNR position with:
🌍 BNR Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold BNR.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 21.86% | 19.06% | $2,186 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 18.58% | 15.78% | $1,858 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 17.49% | 14.69% | $1,749 / yr |
| 🇬🇧 UK ISA | 0% | 21.86% | 19.06% | $2,186 / yr |
| 🇬🇧 UK Taxable | 8.75% | 19.95% | 17.15% | $1,995 / yr |
| 🇨🇦 TFSA | 0% | 21.86% | 19.06% | $2,186 / yr |
| 🇨🇦 CA Taxable | 25% | 16.39% | 13.59% | $1,639 / yr |
| 🇦🇺 Super (pension) | 15% | 18.58% | 15.78% | $1,858 / yr |
| 🇦🇺 AU Taxable | 30% | 15.30% | 12.50% | $1,530 / yr |
| 🇩🇪 DE Taxable | 26.375% | 16.09% | 13.29% | $1,609 / yr |
| 🇫🇷 FR Taxable | 30% | 15.30% | 12.50% | $1,530 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 BNR Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 BNR Dividend Payment Schedule
BNR pays quarterly — 4 times per year. Next ex-div: TBD.
📊 BNR vs Healthcare Benchmarks
How BNR compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for BNR sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ BNR Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Buy | 2026-06-26 | 24,900 | $8.00 | $199.1K | ||
| Buy | 2026-06-24 | 250,000 | $8.00 | $2.00M | ||
| Buy | 2026-06-23 | 5,990 | $7.50 | $44.9K | ||
| Buy | 2026-06-22 | 104,650 | $7.45 | $779.7K | ||
| Buy | 2026-06-16 | 111,110 | $9.00 | $1000.0K | ||
| Buy | 2026-06-12 | 210,000 | $9.25 | $1.94M | ||
| Buy | 2026-06-11 | 24,760 | $8.74 | $216.4K | ||
| Buy | 2026-03-31 | 314,870 | $17.36 | $5.47M | ||
| Other | 2026-03-17 | 1,059,797 | $3.33 | $3.53M | ||
| Other | 2026-03-17 | 116,000 | $0.00 | $23.00 |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Insiders are net buyers — historically a positive signal for dividend sustainability. Last purchase: 2026-06-26
Geographic Revenue Breakdown
Where BNR earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the BNR dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Burning Rock Biotech Limited (BNR) is currently trading at $9.15, 98% below its 52-week high. The current dividend yield is 21.86% based on an annual payout of $2.00 per share.
BNR (Burning Rock Biotech Limited) — 21.86% Dividend Yield Analysis
Burning Rock Biotech Limited (BNR) is a healthcare stock currently trading at $9.15 with a dividend yield of 21.86%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (21.86%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.